Cognitive memory screening and referral program in community pharmacies in the United States

详细信息    查看全文

• 作者：Nathaniel M. Rickles (1)
  Jann B. Skelton (2)
  Jennifer Davis (3) (4)
  Jennifer Hopson (5)
  
• 关键词：Alzheimer’s disease ; Ambulatory care ; Clinical pharmacy services ; Cognitive memory screening ; Community pharmacy ; Dementia ; Physician referral
• 刊名：International Journal of Clinical Pharmacy
• 出版年：2014
• 出版时间：April 2014
• 年：2014
• 卷：36
• 期：2
• 页码：360-367
• 全文大小：204 KB
• 参考文献：1. US Centers for Disease Control. Leading causes of death. http://www.cdc.gov/nchs/fastats/lcod.htm (Accessed 19 Sept 2013).
  2. Batch NL, Mittelman MS, Alzheimer’s Disease International. World Alzheimer’s Report 2012: Overcoming the stigma of dementia. London. http://www.alz.co.uk/research/worldalzheimerreport2012.pdf (Accessed 19 Sept 2013).
  3. Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimers Dement. 2012;8(2).
  4. Alzheimer’s Association. Early Detection. http://www.alz.org/professionals_and_researchers_14897.asp. (Accessed 19 Sept 2013).
  5. Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM. Monetary costs of dementia in the United States. N Engl J Med. 2013;368:1326-4. CrossRef
  6. Hersberger KE, Renggli VP, Nirkko AC, Mathis J, et al. Screening for sleep disorders in community pharmacies: evaluation of a campaign in Switzerland. J Clin Pharm Ther (England). 2006;31:35-1. CrossRef
  7. Pongwecharak J, Treeranurat T. Screening for pre-hypertension and elevated cardiovascular risk factors in a Thai community pharmacy. Pharm World Sci. 2010;32:329-3. CrossRef
  8. Fuller L, Conrad WF, Heaton PC, Panos R, Frede SM, et al. Pharmacist-managed chronic obstructive pulmonary disease screening in a community setting. J Am Pharm Assoc. 2012;52:E59. CrossRef
  9. Johnson JF, Koenigsfeld C, Hughell L, Parsa RA, Bravard S. Bone health screening, education, and referral project in northwest Iowa: creating a model for community pharmacies. J Am Pharm Assoc. 2008;48:379. CrossRef
  10. Liu Y, McDonough RP, Carruthers KM, Doucette WR. Identifying patients at risk of cardiovascular disease: a pharmacist-managed screening event for union workers and their dependents. J Am Pharm Assoc. 2009;49(4):549-3. CrossRef
  11. Johnson JF, Koenigsfeld C, Hughell L, Parsa RA, Bravard S. Bone health screening, education, and referral project in northwest Iowa: creating a model for community pharmacists. J Am Pharm Assoc. 2008;48(3):379-7. CrossRef
  12. Knight DE, Draeger RW, Heaton PC, Patel NC. Pharmacist screening for depression among patients with diabetes in an urban primary care setting. J Am Pharm Assoc. 2008;48(4):518-1. CrossRef
  13. Fera T, Bluml BM, Ellis WM. Diabetes ten city challenge: final economic and clinical results. J Am Pharm Assoc. 2009;49(3):383-1. CrossRef
  14. Park K, Hong WH, Kye SY, Jung E, et al. Community-based intervention to promote breast cancer awareness and screening: the Korean experience. BMC Public Health. 2011;11:468. CrossRef
  15. Hendrie HC, Albert MS, Butters MA, Gao S, Knopman DS, Launer LJ, et al. The NIH cognitive and emotional health project: report of the Critical Evaluation Study Committee. Alzheimers Dement. 2006;2:12-2. CrossRef
  16. Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, K?reholt I, Winblad B, Helkala EL, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer’s disease. Arch Neurol. 2005;62:1556-0. CrossRef
  17. Yaffe K. Metabolic syndrome and cognitive decline. Curr Alzheimer Res. 2007;4:123-. CrossRef
  18. Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K. Central obesity and increased risk of dementia more than three decades later. Neurology. 2008;71:1057-4. CrossRef
  19. Wu W, Brickman AM, Luchsinger J, Ferrazzano P, Pichiule P, Yoshita M, Brown T, et al. The brain in the age of old: the hippocampal formation is targeted differentially by diseases of late life. Ann Neurol. 2008;64:698-06. CrossRef
  20. Solomon A, Kivipelto M, Wolozin B, Zhou J, Whitmer RA. Midlife serum cholesterol and increased risk of Alzheimer’s and vascular dementia three decades later. Dement Geriatr Dis. 2009;28:75-0. CrossRef
  21. Tsivgoulis G, Alexandrov AV, Wadley VG, Unverzagt FW, Go RCP, Moy CS, et al. Association of higher diastolic blood pressure levels with cognitive impairment. Neurology. 2009;73:589-5. CrossRef
  22. Pendlebury ST, Rothwell PM. Prevalence, incidence and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. / Neurology; Published online, 24 Sept 2009. www.thelancet.com/neurology.
  23. Raji CA, Ho AJ, Parikshak NN, Becker JT, Lopez OL, Kuller LH, et al. Brain structure and obesity. Human Brain Mapp http://www.loni.ucla.edu/~thompson/ObesityBrain2009.pdf (Accessed 6 Aug 2009).
  24. Alzheimer’s Association. Know the 10 Signs. 2009. http://www.alz.org/alzheimers_disease_10_signs_of_alzheimers.asp?type=alzFooter#signs (Accessed 20 Sept 2013).
  25. Hill J, McVay JM, Walter-Ginzburg A, Mills CS, Lewis J, Lewis BE, et al. Validation of a brief screen for cognitive impairment (BSCI) administered by telephone for use in the Medicare population. Dis Manag. 2005;8:223-4. CrossRef
  26. Dudkiewicz M, Gold S, Monette J, Le Cruguel J, Bergman H. The clock drawing test for the identification of responders to donepezil. Geriatrics Today. 2002;5:17-0.
  27. Adapted from Duff Canning SJ. c. Neurology. 2004;62:556-62.
  28. Borson S, Scanlan J, Brush M, Vitaliano P, Dokmak A. The mini-cog: a cognitive “vital signs-measure for dementia screening in multi-lingual elderly. Int J Geriatr Psychiatry. 2000;15(11):1021-. CrossRef
  29. Alzheimer’s Foundation of America. I CAN: Investigating Caregivers-Attitudes and Needs. http://www2f.biglobe.ne.jp/~boke/ican2996.pdf (Accessed 20 Sept 2013).
  30. Skelton J. White paper on expanding the role of pharmacists in caring for individuals with Alzheimer’s disease: APhA foundation coordinating council to improve collaboration in supporting patients with Alzheimer’s disease. J Am Pharm Assoc. 2008;48:715-1. CrossRef
  
• 作者单位：Nathaniel M. Rickles (1)
  Jann B. Skelton (2)
  Jennifer Davis (3) (4)
  Jennifer Hopson (5)
  
  1. Northeastern University, Boston, MA, USA
  2. Silver Pennies Consulting, Inc, North Caldwell, NJ, USA
  3. Fred Meyer Pharmacy, Brookings, OR, USA
  4. Continuing Education Department, Oregon State University College of Pharmacy, Corvallis, OR, USA
  5. Kerr Drug, Lenoir, NC, USA
  
• ISSN：2210-7711

文摘

Introduction 12 chain community pharmacy sites located in two geographic areas with the United States implemented easy-to-administer memory screening assessments for patients with risk factors of cognitive memory decline and referred at-risk patients to their physicians. Aim of the study To evaluate the impact of a pharmacy-based cognitive memory screening and referral program, measure patient satisfaction with these advanced clinical services, and assess willingness to pay for cognitive memory screening services. Setting 12 chain pharmacy sites located in two geographic areas—ten Fred Meyer Pharmacies located in the Portland, Oregon area and two Kerr Drug Pharmacies located in North Carolina. Method Pharmacists were educated on Alzheimer’s disease, trained on how to provide cognitive memory screening exams, and equipped with screening and documentation tools. Following each screening, pharmacist provided education and counseling to the patients and referred at-risk patients to physicians for follow-up as appropriate. Main outcome measures Results of screenings; satisfaction of patients; willingness to pay. Results Pharmacists delivered cognitive memory assessments to 161 patients from June to November 2008. 44.1?% of patients experienced at least one cognitive deficiency that required referral to a physician based on the screening conducted. The cognitive memory screening and referral program was highly regarded by patients who completed the satisfaction survey, with 98.4?% of respondents indicating that they were either very satisfied or satisfied with the program. Conclusion Cognitive memory screening can be easily incorporated into clinical service offerings in community pharmacy practice and provides a valuable opportunity to identify patients at-risk and refer them to a physician for appropriate testing and diagnosis.